Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 8/20 | 0.50 |
| ▸ | CDK1 | P06493 | 7/20 | 0.50 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311784 | 0.91 | CDK1 (0.48) | MAPKAPK2CDK1PRKD1PIK3R1PIK3CA | |
| SCHEMBL6320038 | 0.90 | MAPKAPK2 (0.58) | MAPKAPK2CDK1PRKD1MAPT | |
| SCHEMBL6318572 | 0.88 | CDK1 (0.43) | MAPKAPK2CDK1PRKD1MAPTHTT | |
| SCHEMBL6318838 | 0.88 | MAPKAPK2 (0.55) | MAPKAPK2CDK1PRKD1DRD4SMN1; SMN2 | |
| SCHEMBL6313364 | 0.88 | MAPKAPK2 (0.55) | MAPKAPK2CDK1PRKD1DRD4SMN1; SMN2 | |
| SCHEMBL6320066 | 0.86 | MAPKAPK2 (0.56) | MAPKAPK2CDK1PRKD1DRD4MAPT | |
| SCHEMBL6320033 | 0.84 | MAPKAPK2 (0.55) | MAPKAPK2CDK1PRKD1MAPT | |
| SCHEMBL6313536 | 0.84 | KAT2B (0.45) | SMN1; SMN2 | |
| SCHEMBL6314119 | 0.82 | CDK1 (0.51) | MAPKAPK2CDK1PRKD1DRD4MAPT | |
| SCHEMBL6313881 | 0.82 | MAPKAPK2 (0.60) | MAPKAPK2CDK1PRKD1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250765-A1 | Diazepinones as antiviral agents | CHO HIDETSURA | 2005-11-10 | — | — | US | claimed |
| US-20040116410-A1 | Diazepinones as antiviral agents | CHO HIDETSURA (JP) | 2004-06-17 | — | — | US | claimed |
| WO-2002014324-A2 | DIAZEPINONES AS ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-02-21 | — | — | WO | claimed |
| US-20050250765-A1 | Diazepinones as antiviral agents | CHO HIDETSURA | 2005-11-10 | — | — | US | disclosed |
| US-20040116410-A1 | Diazepinones as antiviral agents | CHO HIDETSURA (JP) | 2004-06-17 | — | — | US | disclosed |
| WO-2002014324-A2 | DIAZEPINONES AS ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250765-A1 | Diazepinones as antiviral agents | ZC3HAV1, ECI1, ZC3HAV1L | MAPKAPK2 3952/4885CDK1 274/4885PRKD1 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.